Objectives: Limited screening and delays in diagnosis and linkage-to-care are barriers for hepatitis C virus (HCV) elimination. The LiverTAI study focused on patients tested for HCV using AI technologies to describe their demographic and clinical characteristics and pre-testing patient journeys, reflecting clinical practice in hospitals.
Patients And Methods: LiverTAI is a retrospective, secondary analysis of electronic health records (EHRs) from 6 tertiary Spanish hospitals, extracting unstructured clinical data using natural language processing (NLP) EHRead® technology. Adult subjects with an HCV testing procedure from January 2014 to December 2018 were grouped according to HCV seropositivity and viremia.
Results: From 2,440,358 patients, 16,261 patients were tested for HCV (13,602 [83.6%] HCV seronegative; 2659 [16.4%] seropositive). Active HCV viremia appeared in 37.7% (n=1003) of patients, 18.6% (n=494) had negative viremia, and 43.7% (n=1162) unknown viremia. Patient journeys showed core departments (Gastroenterology, Internal Medicine, and Infectious Disease) and others including Emergency perform ample HCV testing in Spanish hospitals, whereas Medical Oncology lags. Patients were PCR-tested and genotyped significantly faster in core departments (p<.001).
Conclusions: Our results highlight hospital departments responsible for HCV testing. However, further testing was sub-optimal during the study period. Therefore, we underscore the need for HCV screening and reflex testing to accelerate diagnosis and linkage-to-care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gastrohep.2022.10.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disposable and sensitive electrochemical magneto-immunosensor for point-of-care HCV diagnostics: Targeting HCVcAg, the active viremia biomarker, in patient samples.
Biosens Bioelectron
December 2024
Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, United Kingdom. Electronic address:
Early detection of hepatitis C virus (HCV) infection is crucial for eliminating this silent killer, especially in resource-limited settings. HCV core antigen (HCVcAg) represents a promising alternative to the current "gold standard" HCV RNA assays as an active viremia biomarker. Herein, a highly sensitive electrochemical magneto-immunosensor for the HCVcAg was developed.
View Article and Find Full Text PDFPredicting Microvascular Invasion in Liver Transplant Recipients for Hepatocellular Carcinoma.
Cureus
December 2024
Hepatopancreatobiliary and Liver Transplant Surgery, Pakistan Kidney and Liver Institute and Research Center, Lahore, PAK.
Background: Among primary liver tumors, hepatocellular carcinoma (HCC) is considered the most common hepatic tumor. Liver transplantation is one of the curative treatment options for HCC. However, the risk of HCC recurrence after liver transplantation varies and is influenced by various factors.
View Article and Find Full Text PDF[The Preservation of HBV, HCV, HIV Viral Nucleic Acids in Plasma by Dry Spot Method and the Duration of Preservation].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Blood Transfusion Medicine, The Fifth Medical Center of PLA General Hospital, Beijing 100071, China.
Objective: To establish a method for preserving viral nucleic acids in plasma using a blood collection card based on the dry spot method, to predict the duration of nucleic acid preservation by establishing the Arrhenius equation, and to demonstrate the feasibility of this preservation method for the re-testing of nucleic acids in blood samples retained by blood banks.
Methods: Plasma samples positive for HBV, HCV, and HIV nucleic acids were prepared into preservation cards in the form of dry plasma spots for storage. The prepared preservation cards were placed under accelerated storage conditions at 37, 45, 50, and 55 ℃.
Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study.
Front Immunol
January 2025
Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
Article Synopsis
- This study investigated the link between immune checkpoint proteins and liver stiffness in HIV/HCV-coinfected individuals one year after successful HCV treatment, focusing on plasma levels of these proteins and their correlation with liver stiffness measured five years later.
- 39 patients with advanced liver disease who achieved sustained virologic response (SVR) were analyzed, revealing that although liver stiffness decreased over time, it remained persistently high in 61.5% of participants five years after treatment.
- Elevated levels of immune checkpoints BTLA, PD-1, and TIM-3 were associated with this persistently high liver stiffness, indicating a potential ongoing immunological impact on liver health even after HCV eradication.
Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis.
Glob Health Med
December 2024
Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.
Hepatitis B and C (HBV and HCV) testing has been performed in Japan since 2002 and is subsidized by central and prefectural governments. A follow-up program for HBV- or HCV-infected persons was started at that time in Ishikawa Prefecture. This study analyzed the long-term follow-up data from this program.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!